top of page
BIO-RGB_Classic-NegativeTransparent.png

BPA landscape analysis of AI, and an AI-era strategy

extract from the reports delivered to BPA, for the community 

consultation brief

The rapid developments and availability of Artificial Intelligence (AI) technology, alongside associated growth in computational resources and data, have stimulated the widespread adoption of machine learning-based methodologies across research, industry, and society. Understanding the global AI-based technological change within the biosciences is critical to the Australian community. Dimensionalising the impact of this adoption on discovery in the biosciences is non-trivial and beyond operational capabilities.

We can all observe that AI is increasingly integrated into scientific discovery - augmenting and accelerating research, helping scientists generate hypotheses, design experiments, collect and interpret large datasets, and gain insights that might not have been possible using traditional scientific methods alone. For example, the global bioscience community has driven advanced sensor-based technologies (instruments) for decades, augmenting these instruments with physical and statistical methods to interpret resultant datasets. Bioplatforms Australia, as an NCRIS capability, has held a long-standing role in optimally positioning Australian research in this global dynamic. However, now and in many cases, we AI-based methods are at parity and sometimes ahead in quality of interpretation with traditional methods. Is this a passing phase? Will it become pervasive throughout the discovery process? The growth in computer acceleration for AI, combined with the often lower algorithmic complexity of AI, is motivating research endeavours towards the exponential benefits of AI-based methods.

Bioplatforms Australia sought to dimensionalise the change the generative AI era will cause within the omics / molecular life sciences community by commissioning a consultation with the community and providing preliminary advice and recommendations on a framework investment. This is the public summary report.​​

public report

version 1.1

summary

This report provides an extract from 2 of the 7 sections in the report to BPA, namely:

  • PART 1: an AI vision & strateg

  • PART 2: stakeholder consultation

The purpose of sharing this summary is to disseminate some key findings and, in turn, empower the community to progress with well-considered AI-era agendas.

 

The strategy, ideas, and advice may or may not be adopted in part or in whole by BPA - the core purpose of the consultation was to educate BPA and its stakeholders, to develop social license to drive an AI-era initiative, to provide context into the ongoing NDRI strategy, and to discover the differentiated and unique ways the molecular life sciences will benefit from generative-AI informing long term investment.

register

To view online or download, please register below. Registering enables BPA and us to capture interest and engage interested members of the community.

bottom of page